Shots:

• DCGI has granted the marketing authorization to Enzene’s Romiplostim biosimilar for the treatment of chronic ITP in adults
• The company provides all the three dosage strengths of the product (125mcg- 250mcg- and 500mcg)
• Romiplostim is an Fc-peptide fusion protein that increases platelet production through activation of the thrombopoietin receptor. The company’s first biosimilar Teriparatide has been launched in early 2021 for the treatment of osteoporosis

Ref: PRnewswire | Image: Stat News